Nephrology

In a head-to-head real world study, tirzepatide compared with semaglutide resulted in 42%, 20%, and 46% reduced risks for all-cause mortality and major adverse CV and renal events, respectively.

Finerenone treatment achieved a statistically significant reduction in a composite endpoint of CV death and HF events in a population not limited to CKD in T2D, Bayer announced.

Your daily dose of the clinical news you may have missed.

Findings from the large meta-analysis provide strong support for use of both classes to reduce CV and renal disease in adults with type 2 diabetes.

Described as a giant and a pioneer in the hypertension and metabolic fields, Bakris is also remembered so fondly by colleagues as a very special man.

Your daily dose of the clinical news you may have missed.

The pluripotent GLP-1 mimetic reduced risk for renal disease endpoints by 24% and MACE by 18% plus significantly retarded decline in eGFR vs placebo, study authors reported.

The majority of the US adult population meets criteria for subclinical CKM syndrome indicating "an urgent need for population-wide risk reduction measures."

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.